In the phase 3 STAMPEDE trial, the addition of the anti-androgen therapy abiraterone plus the steroid prednisolone to ADT resulted in improved overall survival in patients with mHSPC not previously treated with hormone therapy, as well as improved rates of treatment failure–free survival.
Similarly, the phase 3 ENZAMET trial showed that adding the anti-androgen therapy enzalutamide to ADT resulted in longer survival in patients with mHSPC. The phase 3 ARCHES trial also investigated the addition of abiraterone acetate to ADT in patients with mHSPC. Interim analysis data showed improved radiographic progression-free survival with the addition of enzalutamide, which was consistent across all prespecified subgroups, including disease volume and prior docetaxel chemotherapy. Survival data were not yet mature at the time of analysis.
Intermittent ADT plus chemotherapy continues to be investigated in patients with metastatic prostate cancer. So far, significant improvements in quality of life with use of this treatment method have been noted, including fewer issues with libido and potency.
Learn more about new and emerging treatment options for patients with mHSPC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Bradley Schwartz, Daniel S. Schwartz. Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment - Medscape - Jun 27, 2022.